Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis

Trends in Molecular Medicine

Volumn 14, Issue 2, 2008, Pages 72-81

  Marra, Fabio ^a   Gastaldelli, Amalia ^b   Svegliati Baroni, Gianluca ^c   Tell, Gianluca ^d   Tiribelli, Claudio ^e  

^a Centro di Ricerca   (Italy)

^b CNR   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

APOPTOSIS; CELL DEATH; CYTOTOXICITY; DISEASE COURSE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOGENESIS; LIVER CELL DAMAGE; LIVER FAILURE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS;

ANIMALS; HEPATITIS; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 39149104311     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.12.003     Document Type: Review

References (93)

1. Ludwig J., et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55 (1980) 434-438
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346 (2002) 1221-1231
3. Marchesini G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
4. Utzschneider K.M., and Kahn S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91 (2006) 4753-4761
5. Gastaldelli A., et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (2006) 806-812
6. Bugianesi E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005) 634-642
7. Seppala-Lindroos A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87 (2002) 3023-3028
8. Sanyal A.J., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
9. Gastaldelli A., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and Type 2 diabetic subjects. Gastroenterology 133 (2007) 496-506
10. Samuel V.T., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279 (2004) 32345-32353
11. Musso G., et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42 (2005) 1175-1183
12. Carpentier A., et al. Sensitivity to acute insulin-mediated suppression of plasma free fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes 51 (2002) 1867-1875
13. Petersen K.F., et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 54 (2005) 603-608
14. Nielsen S., et al. Splanchnic lipolysis in human obesity. J. Clin. Invest. 113 (2004) 1582-1588
15. Donnelly K.L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005) 1343-1351
16. Tamura S., and Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005) 1139-1142
17. Kanda H., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116 (2006) 1494-1505
18. Bugianesi E., et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90 (2005) 3498-3504
19. Ouchi N., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
20. Fishman S., et al. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 21 (2007) 53-60
21. Huang W., et al. Hepatic steatosis and plasma dyslipidemia induced by a high-sucrose diet are corrected by an acute leptin infusion. J. Appl. Physiol. 102 (2007) 2260-2265
22. Marra F. Leptin and liver tissue repair: do rodent models provide the answers?. J. Hepatol. 46 (2007) 12-18
23. Arner P. Resistin: yet another adipokine tells us that men are not mice. Diabetologia 48 (2005) 2203-2205
24. Bertolani C., et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am. J. Pathol. 169 (2006) 2042-2053
25. Moschen A.R., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178 (2007) 1748-1758
26. Gervois P., et al. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 145-156
27. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004) 147-152
28. Gastaldelli A., et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29 (2006) 2275-2281
29. Bajaj M., et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 783-789
30. Belfort R., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006) 2297-2307
31. Rubio A., et al. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J. Hepatol. 46 (2007) 708-718
32. Begriche K., et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6 (2006) 1-28
33. Paradies G., et al. The effect of aging and acetyl-L-carnitine on the activity of the phosphate carrier and on the phospholipid composition in rat heart mitochondria. Biochim. Biophys. Acta 1103 (1992) 324-326
34. Sanchez-Alcazar J.A., et al. Tumor necrosis factor-alpha increases the steady-state reduction of Cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J. Biol. Chem. 275 (2000) 13353-13361
35. Gow A.J., and Stamler J.S. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature 391 (1998) 169-173
36. Szabo C., et al. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1753-1758
37. Garcia-Ruiz I., et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 44 (2006) 581-591
38. Leclercq I.A., et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105 (2000) 1067-1075
39. Mari M., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 4 (2006) 185-198
40. Fan C.Y., et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem. 273 (1998) 15639-15645
41. De Minicis S., et al. NADPH oxidase in the liver: defensive, offensive, or fibrogenic?. Gastroenterology 131 (2006) 272-275
42. dela Pena A., et al. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J. Hepatol. 46 (2007) 304-313
43. Schwabe R.F., and Brenner D.A. Nuclear factor-κB in the liver: friend or foe?. Gastroenterology 132 (2007) 2601-2604
44. Xu Z., et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4120-4125
45. Houstis N., et al. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
46. Seki S., et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37 (2002) 56-62
47. Yesilova Z., et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100 (2005) 850-855
48. Sumida Y., et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J. Hepatol. 38 (2003) 32-38
49. Feldstein A.E., et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
50. Wieckowska A., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006) 27-33
51. Ramalho R.M., et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 18 (2006) 21-29
52. Younossi Z.M., et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42 (2005) 665-674
53. Garcia-Ruiz I., et al. Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen alpha 1(I) gene expression in cultured hepatic stellate cells. J. Biol. Chem. 277 (2002) 30551-30558
54. Rahman S.M., et al. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 45 (2007) 1108-1117
55. Watanabe S., et al. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 33 (2005) 161-166
56. Matsuzaka T., et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13 (2007) 1193-1202
57. Yamaguchi K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (2007) 1366-1374
58. Van Gaal L.F., et al. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
59. Ikura Y., et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43 (2006) 506-514
60. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 11 (2005) 183-190
61. Marciniak S.J., and Ron D. Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86 (2006) 1133-1149
62. Dela Pena A., et al. NF-κB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 129 (2005) 1663-1674
63. Arkan M.C., et al. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 11 (2005) 191-198
64. Luedde T., et al. Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007) 119-132
65. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
66. Schattenberg J.M., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43 (2006) 163-172
67. Crespo J., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
68. Haukeland J.W., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44 (2006) 1167-1174
69. Li Z., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003) 343-350
70. Hong F., et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 40 (2004) 933-941
71. Klover P.J., et al. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146 (2005) 3417-3427
72. Howard J.K., and Flier J.S. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol. Metab. 17 (2006) 365-371
73. Brun P., et al. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G571-G578
74. Schwabe R.F., et al. Toll-like receptor signaling in the liver. Gastroenterology 130 (2006) 1886-1900
75. Seki E., et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 13 (2007) 1324-1332
76. Leclercq I.A., et al. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41 (2004) 926-934
77. Bataller R., and Brenner D. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
78. Zoltowska M., et al. Circulating lipoproteins and hepatic sterol metabolism in Psammomys obesus prone to obesity, hyperglycemia and hyperinsulinemia. Atherosclerosis 157 (2001) 85-96
79. Bachman E.S., et al. βAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297 (2002) 843-845
80. Svegliati-Baroni G., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 169 (2006) 846-860
81. Koteish A., and Diehl A.M. Animal models of steatosis. Semin. Liver Dis. 21 (2001) 89-104
82. Parola M., and Robino G. Oxidative stress-related molecules and liver fibrosis. J. Hepatol. 35 (2001) 297-306
83. Canbay A., et al. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
84. Svegliati-Baroni G., et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 29 (1999) 1743-1751
85. Fehrenbach H., et al. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 34 (2001) 943-952
86. Marra F. Thiazolidinediones and hepatic fibrosis: don't wait too long. Gut 55 (2006) 917-919
87. Teixeira-Clerc F., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12 (2006) 671-676
88. Bataller R., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112 (2003) 1383-1394
89. Caligiuri A., et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124 (2003) 504-520
90. Aleffi S., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42 (2005) 1339-1348
91. Saxena N.K., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67 (2007) 2497-2507
92. Kamada Y., et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
93. Xu A., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112 (2003) 91-100